Which type of acute myeloid leukemia is Avonib (Tosovo) mainly used to treat?

Ivosidenib is mainly used to treat patients with acute myeloid leukemia (AML) who carry IDH1 gene mutations. This is a type of hematological malignant tumor with arrested differentiation and poor prognosis. IDH1 Mutation can lead to abnormal accumulation of 2-hydroxyglutarate (2-HG) and other carcinogenic metabolites in tumor cells, inhibiting normal cell differentiation and promoting leukemia progression. Ivonib is the first approved oral small molecule inhibitor targeting this mutation. It can reduce 2-HG levels and promote tumor cell differentiation, thereby improving the clinical prognosis of AML patients.

Clinically, the drug was first approved for treatment by the U.S. Food and Drug Administration (FDA) in 2018 7 Adult patients with relapsed or refractory (R/R) IDH1 mutated acute myeloid leukemia. This indication is particularly targeted at adult patients who have relapsed after standard chemotherapy or who have poor tolerance to chemotherapy. Traditional treatments for these patients have limited effects and generally have a poor prognosis. Studies have shown that in R/R cases, ivonib can significantly improve the response rate and achieve lasting remission in some patients.

As clinical evidence accumulates, FDA has expanded its scope of indications, including newly diagnosed patients, IDH1 mutated AML who are unable to tolerate intensive induction chemotherapy due to age (≥75 years) or comorbidities. Patient. This means that not only relapsed/refractory patients can benefit, but also some newly treated patients who cannot tolerate conventional intensive chemotherapy can also use ivonib as an effective alternative. The expansion is based on clinical trial data showing the drug improves event-free survival and overall survival while being relatively well tolerated.

In actual clinical applications, ivonib is usually used as a targeted therapy alone or in combination with other drugs. Its advantages include strong pertinence, good tolerance, and convenient oral administration. Patients need to regularly monitor blood routine and indicator changes during use, and pay attention to potential risks such as differentiation syndrome. In addition, the detection of IDH1 mutations is a prerequisite for the use of this drug. The mutation status must be clarified through molecular testing such as gene sequencing before treatment can be initiated. Overall, ivosidenib provides an important option for precision medicine for IDH1 mutated AML patients and has shown substantial value in improving response rates and prolonging survival.

Keyword tags:

Avosidenib, IDH1 mutation, acute myeloid leukemia (AML), FDAapproved, indications, targeted therapy, precision medicine

Reference materials:https://en.wikipedia.org/wiki/Ivosidenib